Adam Levy
Investor Relations Contact bij ALAUNOS THERAPEUTICS, INC.
Profiel
Presently, Adam D.
Levy occupies the position of EVP-Corporate Development & Investor Relations at Alaunos Therapeutics, Inc., SVP, Head-Investor Relations & Corporate Affairs at Acrivon Therapeutics, Inc. and Senior VP-Communications & Investor Relations at Turning Point Therapeutics, Inc. Dr. Levy is also on the board of Vesselon, Inc. and Executive Director-Investor Relations at Gilead Sciences, Inc.
Dr. Levy previously held the position of Senior Vice President-Investor Relations at Zentalis Pharmaceuticals, Inc.
Dr. Levy received an undergraduate degree and a doctorate from the University of Illinois and an MBA from Kellogg School of Management.
Actieve functies van Adam Levy
Bedrijven | Functie | Begin |
---|---|---|
ALAUNOS THERAPEUTICS, INC. | Investor Relations Contact | 01-11-2020 |
TURG POIN | Investor Relations Contact | 08-11-2021 |
GILEAD SCIENCES, INC. | Corporate Officer/Principal | - |
ACRIVON THERAPEUTICS, INC. | Investor Relations Contact | 20-07-2023 |
Vesselon, Inc.
Vesselon, Inc. Medical SpecialtiesHealth Technology Vesselon, Inc. develops a portable ultrasound medical device for treating neurodegenerative diseases and brain & ischemic strokes. It commercializes a drug delivery platform that combines ultrasound and microbubbles to deliver the drugs across tissue barriers directly into a target without the need to modify the drug through a process, microbubble assisted sono-therapy. The company was founded by Clayton T. Larsen and Rhodemann Li in 2012 and is headquartered in Norwalk, CT. | Director/Board Member | - |
Eerdere bekende functies van Adam Levy
Bedrijven | Functie | Einde |
---|---|---|
ZENTALIS PHARMACEUTICALS, INC. | Investor Relations Contact | - |
Opleiding van Adam Levy
University of Illinois | Doctorate Degree |
Kellogg School of Management | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 4 |
---|---|
GILEAD SCIENCES, INC. | Health Technology |
ALAUNOS THERAPEUTICS, INC. | Health Technology |
ZENTALIS PHARMACEUTICALS, INC. | Health Technology |
ACRIVON THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Turning Point Therapeutics, Inc.
Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
Vesselon, Inc.
Vesselon, Inc. Medical SpecialtiesHealth Technology Vesselon, Inc. develops a portable ultrasound medical device for treating neurodegenerative diseases and brain & ischemic strokes. It commercializes a drug delivery platform that combines ultrasound and microbubbles to deliver the drugs across tissue barriers directly into a target without the need to modify the drug through a process, microbubble assisted sono-therapy. The company was founded by Clayton T. Larsen and Rhodemann Li in 2012 and is headquartered in Norwalk, CT. | Health Technology |